The resistance to BRAF inhibitors, which is crucial for melanoma prognosis, is caus-ally associated with a mesenchymal-to-amoeboid transition (MAT) and shown as elicited by ligand-independent EphA2 activation [116,126]. This evidence concerns the gene BRAF and melanoma.